

# **Business Update and Future Strategic Direction**

President and Representative Director Kazuo Ushida

#### **Presentation Overview**



### 2017/3 Financial Results

- Operating income of ¥50.9 billion, increase from prior year and forecast
- Net income of -¥7.1 billion, decrease from prior year due to onetime restructuring costs

### 2018/3 Forecast

- Operating profit of **¥45 billion**, decrease due to prior year
- Profit for the period expected to recover to **¥34 billion**

# **Business Environment**

- Imaging Products: Continued market shrinkage
- Precision Equipment: Continued robust FPD lithography demand
- Instruments: Robust automotive/electronic parts related demand
- Medical: Increased demand for ophthalmologic diagnosis due to a globally aging population

# Restructuring Direction


- Achieve break-even of Semiconductor Lithography Business
- Strengthen profit-structure of Imaging Products Business
- Initiate full-scale enhancement of management DNA

### Financial Results for the Year Ended March 31, 2017



- Continued slowing of Imaging Products Business offset by significant increase in Precision Equipment Business, resulting in **¥19.3 billion increase in operating income**
- ¥53.3 billion one-time restructuring costs, resulting in **¥25.3 billion decrease in net income**

#### Operating Income/Net Income




## Forecast for the Year Ending March 31, 2018



- Break-even of Semiconductor Lithography Business, offset by continued imaging market decline and FPD lithography unit sales decline, resulting in **¥5.9 billion decline in operating profit**
- Decline in one-time restructuring costs, resulting in **profit for the period of ¥34 billion**

#### Operating Profit/Profit for the Period



### Business Environment for the Year Ending March 31, 2018



Imaging Products Business

Continued market decline and downward pressure on profitability

Precision Equipment Business

Continued robust FPD lithography demand Mid-to-small sized: Investment shift to expansion of existing lines Large sized: Investment of new lines including G10.5 is growing

Instruments
Business

Stable demand for Biological Microscopes Robust demand related to automotive and electronic parts for Industrial Metrology

**Medical Business** 

Advent of globally aging population causing steady increase of demand for ophthalmologic diagnosis


Company-wide

Forex assumption of US dollar ¥110, Euro ¥120

# First half-year of restructuring is progressing as planned Shift restructuring to "Phase 2" going forward



#### 4 PHASES OF RESTRUCTURING



Target transformation into a company that can generate and sustain ROE of 8% and above in the mid-term

# Strategic direction for phase 2 of restructuring: Year Ending March 31, 2018



1

**Achieve break-even of Semiconductor Lithography Business** 

Complete shift in mindset from top-line to profit centric and sustain profits

2

**Strengthen profit-structure of Imaging Products Business** 

Target a profit-structure able to sustain profit in a declining market. Create a midterm roadmap and initiate a fundamental review of costs

3

Initiate full-scale enhancement of management DNA

Step-up initiatives for implementing new mechanisms